Compare · Head-to-head
AOD-9604 vs Retatrutide.
Evidence, risk, regulatory flags, cost, and vendor coverage compared side by side. We don’t sell peptides — we help you choose between them.
Which should you research first?
Start with AOD-9604, then use the table to confirm fit.
AOD-9604 is the cleaner first read based on the current evidence, risk, and regulatory data stored for this pair. The right answer can still change if your goal, sport testing status, vendor constraints, or monitoring tolerance makes the other option a better fit.
Comparison next step
Personalize this head-to-head.
Take the quiz before converting a comparison into a compound, vendor, or protocol decision.
01· Subject
AOD-9604
GH fragment studied in human obesity trials for lipolytic effects via β-adrenergic pathways.
01 · At a glance
| Decision factor | AOD-9604 | Retatrutide |
|---|---|---|
| Primary fit | fat loss & metabolism research where you want a clear starting point | fat loss & metabolism research where you want a clear starting point |
| Evidence | Tier B | Tier C |
| Risk | med-high | med-high |
| Experience level | intermediate | advanced |
| Budget tier | mid | premium |
| Administration route | oral, subcutaneous | subcutaneous |
02 · Use case & timing
| Decision factor | AOD-9604 | Retatrutide |
|---|---|---|
| Goal fit | Fat Loss & Metabolism | Fat Loss & Metabolism |
| What users compare it for | Modest lipolytic/fat loss signals in trials. Not equivalent to GLP-1 class. | Preliminary human data suggest strong body-weight reduction and metabolic benefit, but the evidence base remains early-stage. |
| Onset timeline | Clinical trials measured outcomes over ~12 weeks; weight loss signals modest. | Expected to follow other incretin agents, with early appetite effects and larger changes over months. |
| Main tradeoff | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. | Evidence and product availability can still be uneven, so documentation matters more than hype. |
03 · Safety & restrictions
| Decision factor | AOD-9604 | Retatrutide |
|---|---|---|
| Adverse effects | Overall tolerability similar to placebo in safety reports; some serious AEs in dose groups (judged unrelated by investigators). | Likely significant GI intolerance profile with limited long-term safety clarity. Broader risk remains uncertain due to limited human exposure. |
| Contraindications | No formal label. | Experimental compound; avoid outside regulated research or clinician-supervised contexts. |
| Interaction notes | Minimal established interactions. | Assume class-like overlap with GLP-1 and GIP therapies; avoid layering with other incretin agents. |
| Regulatory status | Not approved | Investigational |
| FDA flag | FDA status unclear | FDA compounding caution |
| WADA status | WADA S2 | Status unclear |
04 · Age & monitoring
| Decision factor | AOD-9604 | Retatrutide |
|---|---|---|
| Supported age ranges | No age guidance yet | No age guidance yet |
| Life-stage note | Not yet documented | Not yet documented |
| Monitoring burden | Not specified | Not specified |
| Follow-up cadence | Not yet documented | Not yet documented |
05 · Cost & sourcing
| Decision factor | AOD-9604 | Retatrutide |
|---|---|---|
| Typical cycle cost | €963.31 | $150.00 |
| Estimated monthly cost | €321.10 | $150.00 |
| Cost confidence | High confidence | High confidence |
06 · Before you buy
| Decision factor | AOD-9604 | Retatrutide |
|---|---|---|
| Tracked vendor listings | 2 listings | 2 listings |
| Sourcing note | Tracked product pages are available, which makes it easier to review the listing before you click out. | Tracked product pages exist, but naming differences mean the listing needs an extra read before purchase. |
| Stack-friendly? | Usually stack-friendly | Usually stack-friendly |
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Still deciding
Get a plan tailored to you.
The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.